Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 9/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.47 |
| ▸ | TSHR | P16473 | 5/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.44 |
| ▸ | TACR1 | P25103 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5553607 | 0.91 | USP2 (0.47) | USP2OPRD1CYP3A4SMN1; SMN2TSHR | |
| SCHEMBL5559713 | 0.89 | USP2 (0.52) | USP2OPRD1CYP3A4SMN1; SMN2TSHR | |
| SCHEMBL7666272 | 0.89 | USP2 (0.50) | USP2OPRD1CYP3A4SMN1; SMN2TSHR | |
| SCHEMBL5557761 | 0.85 | DDR1 (0.53) | USP2CYP3A4SMN1; SMN2TSHRCYP2C9 | |
| SCHEMBL5558273 | 0.85 | OPRD1 (0.57) | USP2OPRD1CYP3A4SMN1; SMN2TSHR | |
| SCHEMBL5557619 | 0.82 | CYP3A4 (0.49) | USP2OPRD1CYP3A4SMN1; SMN2TSHR | |
| SCHEMBL5557612 | 0.81 | DDR1 (0.56) | USP2OPRD1CYP3A4SMN1; SMN2TSHR | |
| SCHEMBL5559643 | 0.81 | CYP3A4 (0.55) | USP2OPRD1CYP3A4SMN1; SMN2TSHR | |
| SCHEMBL5557657 | 0.81 | USP2 (0.59) | USP2OPRD1CYP3A4SMN1; SMN2TSHR | |
| SCHEMBL5553198 | 0.81 | TACR1 (0.44) | USP2OPRD1CYP3A4SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6482829-B2 | CENTRAL NERVOUS SYSTEM DISORDERS; HEEADACHES, ANTIINFLAMMATORY AGENTS | HOFFMANN-LA ROCHE INC. | 2002-11-19 | — | — | US | claimed |
| US-20020006932-A1 | Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-17 | — | — | US | claimed |
| EP-1292596-B1 | 1,3,8-TRIAZA-SPIRO¬4,5 DECAN-4-ONE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2007-12-19 | — | — | EP | disclosed |
| US-6482829-B2 | CENTRAL NERVOUS SYSTEM DISORDERS; HEEADACHES, ANTIINFLAMMATORY AGENTS | HOFFMANN-LA ROCHE INC. | 2002-11-19 | — | — | US | disclosed |
| US-20020006932-A1 | Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006932-A1 | Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor | TACR1, TACR2, NPR1 | USP2 3849/4885OPRD1 25/4885CYP3A4 3223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.